Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

507 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-19

Study Completion Date

2024-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

NCT06129851

Stage IIC Prostate Cancer AJCC v8 Stage III Prostate Cancer AJCC v8 Stage IV Prostate Cancer AJCC v8

NOT_YET_RECRUITING PHASE2

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

NCT03085095

Prostate Cancer

COMPLETED PHASE3

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129

Metastatic Castration-Resistant Prostate Cancer Metastatic Castration-Sensitive Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer

COMPLETED PHASE1

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995

Androgen Deprivation Therapy Locally Advanced Prostate Cancer

RECRUITING PHASE1

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

NCT05605964

Prostate Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the United States. Androgen deprivation therapy (ADT) such as injectable luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide) is the standard of care for PC patients. ADT treatment can suppress testosterone level to castrate level and delay the progression of the disease.

Relugolix is a recently approved oral GnRH antagonist. While the introduction of relugolix has offered a unique opportunity for patients with PC, it's vital to understand how it is being used in real-world.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relugolix patients

Patients who have initiated relugolix

Relugolix

Intervention Type DRUG

relugolix

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Relugolix

relugolix

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male with ≥ 1 diagnosis for PC
* Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
* Index date: the initiation date of relugolix
* At least 18 years old at the index date